title: Model of tumor-associated epigenetic changes of HER2, ER, and PgR expression in invasive breast cancer phenotypes.
abstract: This theoretic paper is an attempt to apply the epigenetic progenitor model of human cancer origin, proposed by Feinberg et al. (Nat Rev Genet 7:21-33, 2006), to the reported phenotype features of invasive breast cancer. The model is based on the idea that expression of estrogen receptors (ER), progesterone receptors (PgR), and HER2 molecules in breast tumors is either remnants of the tissue stem cell from which the tumor has developed or a newly acquired tumor-associated epigenetic feature. HER2 overexpression is considered as an example of the tumor-associated epigenetic changes. The model makes a simple distinction regarding the possible types of ER and PgR expression: the "functional" steroid hormone receptors are inherited from pretumoral tissue stem cells, while the "dysfunctional" steroid hormone receptors are acquired during tumorigenesis from initially ER-PgR-negative cells. In the former, estrogen binding increases the PgR expression while progesterone binding decreases the expression of ER and PgR. Since the estrogen-dependent PgR expression works only in cells with functional ERs, the expected share of tumors with functional ER and PgR receptors is in the model calculated as the squared probability of expressing the PgRs. Reported data from various trials are pooled together to find out phenotype shares (ER+PgR+ makes 62.03 %, ER+PgR- 16.43 %, ER-PgR+ 3.06, and ER-PgR- 18.48 %). By applying the model on these shares, the proposed share of tumors with the functional ER+PgR+ phenotype was 38.48 %, while the share of tumors with the dysfunctional ER+PgR+ was 23.55 %. The presented model suggests that both luminal A and luminal B tumor types are heterogeneous regarding the steroid receptor expression. Some tumors have functional and some have dysfunctional steroid receptors. If these predicted subgroups exist, their detection in the clinical practice might substantially improve treatment options, particularly in the premenopausal setting.
authors: Department of Physiology, Osijek Medical Faculty, J Huttlera 4, 31000, Osijek, Croatia. sven@jware.hr
authors: Sven
authors: S
authors: Kurbel
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics*; D044127:Epigenesis, Genetic; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000235:genetics / Q000378:metabolism*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011982:Receptors, Prostaglandin; C508053:ERBB2 protein, human
references: Climacteric. 2013 Aug;16 Suppl 1:54-68
references: 23336704
references: Anticancer Res. 1987 Jan-Feb;7(1):119-23
references: 3032071
references: Arch Pathol Lab Med. 1996 Oct;120(10):970-3
references: 12046611
references: J Clin Oncol. 2007 Oct 20;25(30):4772-8
references: 17876012
references: Theor Biol Med Model. 2012 Aug 07;9:35
references: 22870942
references: Cancer Causes Control. 1999 Oct;10(5):431-7
references: 10530614
references: Nat Rev Genet. 2006 Jan;7(1):21-33
references: 16369569
references: Endocr Rev. 2013 Feb;34(1):130-62
references: 23303565
references: Tumour Biol. 2013 Feb;34(1):1-7
references: 23208673
references: Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004143
references: 22786488
references: Endocrinology. 1978 Nov;103(5):1742-51
references: 748014
references: Br J Cancer. 1991 Oct;64(4):764-8
references: 1911227
references: Gynecol Oncol. 2006 May;101(2):214-23
references: 16325240
references: J Clin Oncol. 2003 May 15;21(10):1973-9
references: 12743151
references: Breast Cancer Res Treat. 1990 Feb;15(2):109-17
references: 2322649
references: J Clin Oncol. 1984 Oct;2(10):1102-9
references: 6491696
references: Cancer. 1998 Aug 15;83(4):698-705
references: 9708933
references: J Clin Pathol. 2013 Jun;66(6):530-42
references: 23436929
references: J Steroid Biochem Mol Biol. 1993 Apr;45(4):315-9
references: 8499339
references: J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61
references: 16145046
references: Jpn J Cancer Res. 1989 Mar;80(3):244-8
references: 2524460
references: Breast Cancer Res. 2007;9(1):R6
references: 17239243